Skip to main content
Linda Laux, MD, Pediatrics, Chicago, IL

LindaCarolLauxMD

Pediatrics Chicago, IL

Child Neurology

Assistant Professor in Pediatrics, Northwestern University Medical School

Dr. Laux is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Laux's full profile

Already have an account?

  • Office

    225 E Chicago Ave
    #29
    Chicago, IL 60611
    Phone+1 312-227-3540
    Fax+1 312-227-6940

Education & Training

  • Phoenix Children's Hospital
    Phoenix Children's HospitalFellowship, Child Neurology, 1994 - 1997
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Pediatrics, 1990 - 1993
  • Saint Louis University School of Medicine
    Saint Louis University School of MedicineClass of 1990

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2000 - 2026
  • AZ State Medical License
    AZ State Medical License 1994 - 2010
  • American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
  • American Board of Psychiatry and Neurology Clinical Neurophysiology
  • American Board of Psychiatry and Neurology Epilepsy

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • The Design and Impact of a Hospital-Based Neurodiagnostic Training Program in Electroencephalography and Polysomnography Technology
    The Design and Impact of a Hospital-Based Neurodiagnostic Training Program in Electroencephalography and Polysomnography TechnologyAugust 8th, 2024
  • Antisense Oligonucleotide Shows Potential in Dravet Syndrome
    Antisense Oligonucleotide Shows Potential in Dravet SyndromeDecember 9th, 2022
  • Stoke Therapeutics : Presents Data from a Combined Interim Analysis of the Phase 1/2a - Form 8-K
    Stoke Therapeutics : Presents Data from a Combined Interim Analysis of the Phase 1/2a - Form 8-KDecember 2nd, 2022
  • Join now to see all